DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced that the Office of the Drug Controller General (DCGI) in India has granted registration for the Company’s Impella 2.5 and Impella 5.0 circulatory support technologies. Abiomed plans to market these advanced medical devices through Interventional Technologies, Ltd, its distributor based in Mumbai, India.
